• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

绝经后骨质疏松症有效治疗的障碍:一项关于患者和从业者观点的定性研究

Barriers to Effective Postmenopausal Osteoporosis Treatment: A Qualitative Study of Patients' and Practitioners' Views.

作者信息

Alami Sophie, Hervouet Lucile, Poiraudeau Serge, Briot Karine, Roux Christian

机构信息

Interlis, Paris, France.

Centre de Sociologie des Organisations, Institut des Sciences Politiques, UMR 7116, CNRS, Paris, France.

出版信息

PLoS One. 2016 Jun 29;11(6):e0158365. doi: 10.1371/journal.pone.0158365. eCollection 2016.

DOI:10.1371/journal.pone.0158365
PMID:27355576
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4927112/
Abstract

BACKGROUND

Only a minority of patients at high risk for osteoporotic fracture receive treatment.

OBJECTIVE

Study patients' and physicians' views regarding postmenopausal osteoporosis (PMO) to identify impediments to good care.

METHODS

A qualitative study involving 18 physicians and 37 women (age 57-87) with PMO.

RESULTS

All women interviewed considered PMO to be somewhat normal wear-and-tear associated with old age. The women identified a large number of "causes" for osteoporosis but finally viewed it as chance. They all described its progression as slow. Three representations of PMO severity were identified: some women tended to interpreted it as benign (21), others tended to dramatize it (11), and the rest were uncertain (5). These representations did not appear linked to age or fracture. Even the women who associated fracture and PMO were uncertain of the link between them. Fractures were considered to be random events, independent of osteoporosis. Women received general life-style recommendations from their physicians positively, but did not connect them specifically to osteoporosis. Indeed, these recommendations, along with the fear of side effects, the absence of tangible results of treatments, the view of PMO as a natural process, and the representations of PMO severity are factors that may deter treatments and impact compliance. As for the physicians, they identified eight risk factors, recognizing menopause as central to PMO and recognized the link between risk of fracture and PMO. However, some considered the impact of fractures to be limited in time, and viewed PMO as a "benign" disease. Seeing the progression of PMO as slow and inevitable reduced their urgency to diagnose and treat it as compared to other diseases. Some physicians acknowledged limited mastery of the existing therapeutic arsenal and unsuccessful handling of patient compliance.

CONCLUSION

Women's and physicians' perspectives on PMO converged to trivialize postmenopausal osteoporosis and thus disqualify it as a legitimate disease. A better understanding of women's and physicians' views, practices, and concerns related to PMO can improve osteoporosis management.

摘要

背景

仅有少数骨质疏松性骨折高危患者接受治疗。

目的

研究患者和医生对绝经后骨质疏松症(PMO)的看法,以确定优质护理的障碍因素。

方法

一项定性研究,涉及18名医生和37名患有PMO的女性(年龄57 - 87岁)。

结果

所有接受访谈的女性都认为PMO在一定程度上是与老年相关的正常磨损。这些女性确定了大量骨质疏松症的“病因”,但最终认为这是偶然因素。她们都描述其进展缓慢。确定了三种PMO严重程度的表现形式:一些女性倾向于将其解释为良性(21人),另一些女性倾向于夸大其严重性(11人),其余的则不确定(5人)。这些表现形式似乎与年龄或骨折无关。即使是那些将骨折与PMO联系起来的女性,也不确定两者之间的联系。骨折被认为是随机事件,与骨质疏松症无关。女性积极接受医生给出的一般生活方式建议,但并未将其与骨质疏松症具体联系起来。实际上,这些建议,以及对副作用的恐惧、治疗缺乏切实效果、将PMO视为自然过程的观点以及PMO严重程度的表现形式,都是可能阻碍治疗并影响依从性的因素。至于医生,他们确定了八个风险因素,认识到绝经是PMO的核心因素,并认识到骨折风险与PMO之间的联系。然而,一些医生认为骨折的影响在时间上是有限的,并将PMO视为一种“良性”疾病。与其他疾病相比,将PMO的进展视为缓慢且不可避免降低了他们诊断和治疗的紧迫性。一些医生承认对现有治疗手段掌握有限,且在处理患者依从性方面不太成功。

结论

女性和医生对PMO的看法趋于将绝经后骨质疏松症视为平常之事,从而使其失去作为一种合理疾病的资格。更好地理解女性和医生与PMO相关的看法、做法和担忧,可改善骨质疏松症的管理。

相似文献

1
Barriers to Effective Postmenopausal Osteoporosis Treatment: A Qualitative Study of Patients' and Practitioners' Views.绝经后骨质疏松症有效治疗的障碍:一项关于患者和从业者观点的定性研究
PLoS One. 2016 Jun 29;11(6):e0158365. doi: 10.1371/journal.pone.0158365. eCollection 2016.
2
Osteoporosis prevention: where are the barriers to improvement in a French general population? A qualitative study.骨质疏松症预防:法国普通人群中改善的障碍在哪里?一项定性研究。
Osteoporos Int. 2019 Jan;30(1):177-185. doi: 10.1007/s00198-018-4720-5. Epub 2018 Oct 10.
3
Fear of falling, fracture history, and comorbidities are associated with health-related quality of life among European and US women with osteoporosis in a large international study.在一项大型国际研究中,对于欧美患有骨质疏松症的女性而言,害怕跌倒、骨折史和合并症与健康相关生活质量相关。
Osteoporos Int. 2013 Dec;24(12):3001-10. doi: 10.1007/s00198-013-2408-4. Epub 2013 Jun 11.
4
Characterisation of patients with postmenopausal osteoporosis in French primary healthcare.法国初级医疗保健中绝经后骨质疏松症患者的特征分析。
Drugs Aging. 2007;24(7):603-14. doi: 10.2165/00002512-200724070-00007.
5
Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis.阿巴洛肽用于降低绝经后骨质疏松症妇女的非椎体和椎体骨折风险:一项网络荟萃分析。
Osteoporos Int. 2019 Jul;30(7):1465-1473. doi: 10.1007/s00198-019-04947-2. Epub 2019 Apr 6.
6
Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice.澳大利亚全科医学中的骨质疏松症管理:当前骨质疏松症治疗模式的分析及实践中的差距。
BMC Fam Pract. 2020 Feb 12;21(1):32. doi: 10.1186/s12875-020-01103-2.
7
Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.在德国、奥地利、希腊和比利时接受地诺单抗治疗的绝经后骨质疏松症女性的持续性、依从性和服药行为:一项欧洲非干预性研究的12个月结果
Osteoporos Int. 2015 Oct;26(10):2479-89. doi: 10.1007/s00198-015-3164-4. Epub 2015 May 28.
8
Osteoporosis prevention: Where are the barriers to improvement in French general practitioners? A qualitative study.骨质疏松症预防:法国全科医生改善的障碍在哪里?一项定性研究。
PLoS One. 2019 Jul 16;14(7):e0219681. doi: 10.1371/journal.pone.0219681. eCollection 2019.
9
Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims.医生对患者骨质疏松症药物依从性的认知与从药房索赔中观察到的患者依从性比较。
Curr Med Res Opin. 2010 Apr;26(4):777-85. doi: 10.1185/03007990903579171.
10
Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women.巴多昔芬与口服双膦酸盐类药物预防绝经后骨质疏松症女性椎体骨折的间接比较
Curr Med Res Opin. 2014 Aug;30(8):1617-26. doi: 10.1185/03007995.2014.908279. Epub 2014 May 2.

引用本文的文献

1
Patient perceptions of osteoporosis management: a qualitative pilot study by a patient advisory group.患者对骨质疏松症管理的认知:患者咨询小组开展的一项定性试点研究
Arch Osteoporos. 2025 Jan 15;20(1):9. doi: 10.1007/s11657-024-01486-0.
2
Exhaled breath metabolites reveal postmenopausal gut-bone cross-talk and non-invasive markers for osteoporosis.呼出气代谢物揭示绝经后肠道与骨骼的相互作用及骨质疏松症的非侵入性标志物。
Commun Med (Lond). 2024 Dec 28;4(1):279. doi: 10.1038/s43856-024-00723-4.
3
Perspectives of healthcare providers on osteoporosis, falls and fracture risk: a systematic review and thematic synthesis of qualitative studies.医务人员对骨质疏松症、跌倒和骨折风险的看法:系统评价和定性研究的主题综合分析。
Arch Osteoporos. 2024 Sep 24;19(1):90. doi: 10.1007/s11657-024-01446-8.
4
Short-term risk of fracture is increased by deficits in cortical and trabecular bone microarchitecture independent of DXA BMD and FRAX: Bone Microarchitecture International Consortium (BoMIC) prospective cohorts.短期骨折风险增加与皮质骨和小梁骨微结构缺陷有关,与 DXA BMD 和 FRAX 无关:骨微结构国际联合会(BoMIC)前瞻性队列研究。
J Bone Miner Res. 2024 Oct 29;39(11):1574-1583. doi: 10.1093/jbmr/zjae143.
5
Fracture liaison service-a multidisciplinary approach to osteoporosis management.骨折联络服务——骨质疏松症管理的多学科方法。
Osteoporos Int. 2024 Oct;35(10):1719-1727. doi: 10.1007/s00198-024-07181-7. Epub 2024 Jul 18.
6
Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study.用于预防骨质疏松性脆性骨折的双膦酸盐替代方案:BLAST-OFF,一项混合方法研究。
Health Technol Assess. 2024 Apr;28(21):1-169. doi: 10.3310/WYPF0472.
7
Healthcare professionals' perspectives and experiences of osteoporosis medication treatment: a qualitative systematic review.医护人员对骨质疏松症药物治疗的看法和体验:定性系统评价。
Arch Osteoporos. 2024 Jan 8;19(1):8. doi: 10.1007/s11657-023-01359-y.
8
Underlying motivations hampering Flemish primary care physicians from overcoming the barriers in osteoporosis care: an EMR-facilitated clinical reasoning study.阻碍佛兰德初级保健医生克服骨质疏松症护理障碍的潜在动机:一项基于电子病历的临床推理研究。
BMC Health Serv Res. 2023 Dec 16;23(1):1428. doi: 10.1186/s12913-023-10441-7.
9
A Delphi consensus on the management of Spanish patients with osteoporosis at high risk of fracture: OSARIDELPHI study.德尔福共识:西班牙高骨折风险骨质疏松症患者的管理:OSARIDELPHI 研究。
Arch Osteoporos. 2023 Aug 23;18(1):110. doi: 10.1007/s11657-023-01318-7.
10
Impact of postmenopausal osteoporosis on the lives of Omani women and the use of cultural and religious practises to relieve pain: A hermeneutic phenomenological study.绝经后骨质疏松症对阿曼妇女生活的影响以及使用文化和宗教习俗缓解疼痛:一种阐释现象学研究。
Health Expect. 2023 Dec;26(6):2278-2292. doi: 10.1111/hex.13824. Epub 2023 Jul 26.

本文引用的文献

1
Clinician's Guide to Prevention and Treatment of Osteoporosis.骨质疏松症防治临床指南
Osteoporos Int. 2014 Oct;25(10):2359-81. doi: 10.1007/s00198-014-2794-2. Epub 2014 Aug 15.
2
Osteoporosis medication dispensing for older Australian women from 2002 to 2010: influences of publications, guidelines, marketing activities and policy.2002年至2010年澳大利亚老年女性骨质疏松症药物配给情况:出版物、指南、营销活动及政策的影响
Pharmacoepidemiol Drug Saf. 2014 Dec;23(12):1303-11. doi: 10.1002/pds.3703. Epub 2014 Aug 30.
3
Patient perceptions of provider barriers to post-fracture secondary prevention.患者对骨折后二级预防中医疗服务提供者障碍的认知。
Osteoporos Int. 2014 Nov;25(11):2581-9. doi: 10.1007/s00198-014-2804-4. Epub 2014 Aug 1.
4
Critical impact of patient knowledge and bone density testing on starting osteoporosis treatment after fragility fracture: secondary analyses from two controlled trials.患者知识与骨密度检测对脆性骨折后启动骨质疏松症治疗的关键影响:两项对照试验的二次分析
Osteoporos Int. 2014 Sep;25(9):2173-9. doi: 10.1007/s00198-014-2728-z. Epub 2014 May 7.
5
Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.美国 2000 年至 2009 年脆性骨折后骨质疏松症管理率下降。
J Bone Joint Surg Am. 2014 Apr 2;96(7):e52. doi: 10.2106/JBJS.L.01781.
6
Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011.2002年至2011年间美国髋部骨折患者使用骨质疏松症药物的情况。
J Bone Miner Res. 2014 Sep;29(9):1929-37. doi: 10.1002/jbmr.2202.
7
Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA).欧盟的骨质疏松症:医疗管理、流行病学和经济负担。这份报告是与国际骨质疏松基金会(IOF)和欧洲制药工业协会联合会(EFPIA)合作编写的。
Arch Osteoporos. 2013;8(1):136. doi: 10.1007/s11657-013-0136-1. Epub 2013 Oct 11.
8
Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012.美国 2002-2012 年口服和静脉用双膦酸盐治疗骨质疏松症的趋势。
Bone. 2013 Dec;57(2):423-8. doi: 10.1016/j.bone.2013.09.008. Epub 2013 Sep 21.
9
Understanding osteoporosis and fractures: an introduction to the use of qualitative research.了解骨质疏松症与骨折:质性研究应用指南
Arch Orthop Trauma Surg. 2014 Feb;134(2):207-17. doi: 10.1007/s00402-013-1799-1. Epub 2013 Jul 17.
10
Non-pharmacological strategies used by patients at high risk for future fracture to manage fracture risk--a qualitative study.高骨折风险患者用于管理骨折风险的非药物策略——一项定性研究。
Osteoporos Int. 2014 Jan;25(1):281-8. doi: 10.1007/s00198-013-2405-7. Epub 2013 Jun 6.